A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

IMMUNE CHECKPOINT INHIBITOR TOXICITY (I-CHECKIT):  A PROSPECTIVE OBSERVATIONAL STUDY

MSK 23-098 A Phase II study of IO102/IO103 and nivolumab-relatlimab fixed dose combination in untreated, unresectable Stage III/IV melanoma

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

A032101 Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

EA9181 A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults

Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with State II/III BRAF V600E Colon Cancer

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer